NAC1, A POZ/BTB protein interacts with Parkin and may contribute to Parkinson's disease

Neuroscience. 2014 Jan 17:257:86-95. doi: 10.1016/j.neuroscience.2013.11.001. Epub 2013 Nov 11.

Abstract

Loss-of-function in the Parkin protein is thought to play a part in causing neuronal cell death in patients with Parkinson's disease. This study explores the effect of Parkin degradation, via the overexpression of nucleus accumbens 1 (NAC1), on cell viability. It was found that NAC1 and Parkin are co-localized within the cell and interact with one another, leading to a decrease in Parkin levels. Moreover, NAC1 down-regulates Parkin by presenting it for ubiquitin-dependent proteasome degradation, which causes a decrease in proteasomal activity in neuronal cells. Consequently, this decrease in proteasomal activity leads to an increase in the cells' susceptibility to proteasome inhibition-induced toxicity. It was also found that Parkin and NAC1 are key proteins found to be present mainly in the cytoplasm and are co-localized in neurons of Parkinson's disease patients. Interestingly, mutation in the POZ/BTB domain (Q23L) of NAC1 disrupts the co-localization and interaction of NAC1 with Parkin and it further abrogates the proteasome inhibition-induced toxicity. We further observed that co-transfection of the mutant form of NAC1 with Parkin reversed the proteasome activity and 20S proteasome protein levels. These results indicate a novel interaction between NAC1 and Parkin that leads to neuronal cell death, a main characteristic in Parkinson's disease.

Keywords: 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide; 4′,6-diamidino-2-phenylindole; DAPI; GAPDH; GST; MTT; NAC; PBS; PCR; PD; Parkinson’s disease; SDS–PAGE; UPS; aggregates; co-immunoprecipitation; co-localization; degradation; down-regulation; glutathione S-transferase; glyceraldehyde 3-phosphate dehydrogenase; nucleus accumbens; phosphate-buffered saline; polymerase chain reaction; proteasome; sodium dodecyl sulfate–polyacrylamide gel electrophoresis; ubiquitin–proteasome system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Animals
  • Brain / pathology
  • Cell Line, Transformed
  • Central Nervous System / metabolism
  • Cysteine Proteinase Inhibitors / pharmacology
  • Cytoplasm / metabolism
  • Down-Regulation / drug effects
  • Down-Regulation / genetics
  • Down-Regulation / physiology*
  • Glutathione Transferase / metabolism
  • Humans
  • Immunoprecipitation
  • Leupeptins / pharmacology
  • Male
  • Mice
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism*
  • Neurons / cytology
  • Parkinson Disease / pathology
  • Proteasome Endopeptidase Complex
  • Repressor Proteins / genetics
  • Repressor Proteins / metabolism*
  • Ubiquitin-Protein Ligases / genetics
  • Ubiquitin-Protein Ligases / metabolism*

Substances

  • Cysteine Proteinase Inhibitors
  • Leupeptins
  • Nacc1 protein, mouse
  • Nerve Tissue Proteins
  • Repressor Proteins
  • Ubiquitin-Protein Ligases
  • parkin protein
  • Glutathione Transferase
  • Proteasome Endopeptidase Complex
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde